Research and analysis

ACRE advice: application for a trial of genetically modified Bordetella Pertussis (21/R53/01) and (22/R53/01)

ACRE's advice on an application from ILiAD Biotechnologies to carry out a trial of genetically modified Bordetella Pertussis.

• From: Advisory Committee on Releases to the Environment
• Published: 23 June 2022

Documents

Advice on an application for deliberate release of a GMO for research and development purposes

PDF, 77.5 KB, 4 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

These documents are the advice of the Advisory Committee on Releases to the Environment (ACRE) to government on 2 applications from ILiAD Biotechnologies LLC to carry out trials, in subsequent years, of genetically modified Bordetella Pertussis.

The committee advised that the risks to human health and the environment from this trial are extremely low.

Published 23 June 2022